{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:10:14Z","timestamp":1790651414641,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The real-world clinical and economic burden of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation has not been comprehensively studied in France. Clinical outcomes, healthcare resource utilization and costs associated with acute GVHD (aGVHD), chronic GVHD (cGVHD), acute plus chronic GVHD (a+cGVHD) versus no GVHD were compared using French administrative claims data. After propensity score matching, 1934, 408, and 1268 matched pairs were retained for the aGVHD, cGVHD, and a+cGVHD cohorts, respectively. Compared with patients with no GVHD, odds of developing severe infection were greater in patients with aGVHD (odds ratio: 1.7 [95% confidence interval: 1.4, 2.1]). Compared with patients with no GVHD, mortality rates were higher in patients with aGVHD (rate ratio (RR): 1.6 [1.4, 1.7]) and with a+cGVHD (RR: 1.1 [1.0, 1.2]) but similar in patients with cGVHD (RR: 0.9 [0.7, 1.1]). Mean overnight hospital admission rates per patient-year were significantly higher in patients with aGVHD and a+cGVHD compared with no GVHD. Total direct costs (range \u20ac174,482\u2013332,557) were 1.2, 1.5, and 1.9 times higher for patients with aGVHD, cGVHD, and a+cGVHD, respectively, versus patients with no GVHD. These results highlight the significant unmet need for effective treatments of patients who experience GVHD.<\/jats:p>","DOI":"10.1038\/s41409-023-01930-8","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T07:04:03Z","timestamp":1676012643000},"page":"514-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4553-3065","authenticated-orcid":false,"given":"David","family":"Michonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-1307","authenticated-orcid":false,"given":"Nadia","family":"Quignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maebh","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-5046","authenticated-orcid":false,"given":"Anita","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-5305","authenticated-orcid":false,"given":"Kris","family":"Thiruvillakkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"1930_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/bmt.2013.51","volume":"48","author":"JR Passweg","year":"2013","unstructured":"Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 2013;48:1161\u20137. https:\/\/doi.org\/10.1038\/bmt.2013.51.","journal-title":"Bone Marrow Transplant"},{"key":"1930_CR2","unstructured":"Transplant Activity Survey. The European Society for Blood and Marrow Transplantation Web site. https:\/\/www.ebmt.org\/registry\/transplant-activity-survey Accessed 15 Mar 2022."},{"key":"1930_CR3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","volume":"55","author":"JR Passweg","year":"2020","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus. Bone Marrow Transplant. 2020;55:1604\u201313. https:\/\/doi.org\/10.1038\/s41409-020-0826-4.","journal-title":"Bone Marrow Transplant"},{"key":"1930_CR4","doi-asserted-by":"publisher","first-page":"A524","DOI":"10.1016\/j.jval.2014.08.1647","volume":"17","author":"A Thiebaut","year":"2014","unstructured":"Thiebaut A, Lafuma A, Bureau I, Boyaval G, Bensoussan C, Godard C. Allogeneic stem cell transplant with graft versus host disease in France in 2012 based on national hospital databases (Pmsi). Value Health. 2014;17:A524. https:\/\/doi.org\/10.1016\/j.jval.2014.08.1647.","journal-title":"Value Health"},{"key":"1930_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"J Ferrara","year":"2009","unstructured":"Ferrara J, Levine J, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(09)60237-3.","journal-title":"Lancet"},{"key":"1930_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.medcli.2018.07.012","volume":"152","author":"DF Moreno","year":"2019","unstructured":"Moreno DF, Cid J. Graft-versus-host disease. Med Clin. 2019;152:22\u20138. https:\/\/doi.org\/10.1016\/j.medcli.2018.07.012.","journal-title":"Med Clin"},{"key":"1930_CR7","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1182\/blood-2002-07-2231","volume":"101","author":"G Socie","year":"2003","unstructured":"Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373\u201385. https:\/\/doi.org\/10.1182\/blood-2002-07-2231.","journal-title":"Blood"},{"key":"1930_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbmt.2019.10.028","volume":"26","author":"J Yu","year":"2020","unstructured":"Yu J, Judy JT, Parasuraman S, Sinha M, Weisdorf D. Inpatient healthcare resource utilization, costs, and mortality in adult patients with acute graft-versus-host disease, including steroid-refractory or high-risk disease, following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:600\u20135. https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.028.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1930_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.bbmt.2018.12.839","volume":"25","author":"BH Johnson","year":"2019","unstructured":"Johnson BH, Taylor A, Kim G, Drahos J, Yang J, Akbari M, et al. Clinical outcomes and healthcare resource utilization for gastrointestinal acute graft-versus-host disease after allogeneic transplantation for hematologic malignancy: a retrospective US administrative claims database analysis. Biol Blood Marrow Transplant. 2019;25:834\u201341. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.839.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1930_CR10","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1007\/s00520-020-05382-4","volume":"28","author":"J Yu","year":"2020","unstructured":"Yu J, Lal L, Anderson A, DuCharme M, Parasuraman S, Weisdorf D. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Support Care Cancer. 2020;28:5491\u20139. https:\/\/doi.org\/10.1007\/s00520-020-05382-4.","journal-title":"Support Care Cancer"},{"key":"1930_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","volume":"35","author":"J Yu","year":"2019","unstructured":"Yu J, Parasuraman S, Shah A, Weisdorf D. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation. Curr Med Res Opin. 2019;35:983\u20138. https:\/\/doi.org\/10.1080\/03007995.2018.1551193.","journal-title":"Curr Med Res Opin"},{"key":"1930_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40261-021-01087-6","volume":"41","author":"DS Hooker","year":"2021","unstructured":"Hooker DS, Grabe-Heyne K, Henne C, Bader P, Toumi M, Furniss SJ. Improved therapeutic approaches are needed to manage graft-versus-host disease. Clin Drug Investig. 2021;41:929\u201339.","journal-title":"Clin Drug Investig"},{"key":"1930_CR13","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti N, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u201367.","journal-title":"Lancet Haematol"},{"key":"1930_CR14","unstructured":"Chao NJ. Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease. In: Negrin RS, editor. UpToDate; 2020."},{"key":"1930_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/bmt.2016.225","volume":"52","author":"I Garcia-Cadenas","year":"2017","unstructured":"Garcia-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplant. 2017;52:107\u201313. https:\/\/doi.org\/10.1038\/bmt.2016.225.","journal-title":"Bone Marrow Transplant"},{"key":"1930_CR16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","unstructured":"Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1102\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.020.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1930_CR17","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","volume":"76","author":"AK Singh","year":"2016","unstructured":"Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res. 2016;76:6445\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1311.","journal-title":"Cancer Res"},{"key":"1930_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.V93.2.467","volume":"93","author":"TN Small","year":"1999","unstructured":"Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93:467\u201380.","journal-title":"Blood"},{"key":"1930_CR19","doi-asserted-by":"publisher","unstructured":"Atilla E, Atilla PA, Toprak SK, Demirer T. A review of late complications of allogeneic hematopoietic stem cell transplantations. Clin Transplant. 2017;31. https:\/\/doi.org\/10.1111\/ctr.13062.","DOI":"10.1111\/ctr.13062"},{"key":"1930_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bbmt.2011.08.009","volume":"18","author":"ZP Yu","year":"2012","unstructured":"Yu ZP, Ding JH, Wu F, Liu J, Wang J, Cheng J, et al. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. Biol Blood Marrow Transplant. 2012;18:593\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2011.08.009.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1930_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","volume":"22","author":"JH Young","year":"2016","unstructured":"Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22:359\u201370. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.013.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1930_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2013-12-547349","volume":"124","author":"C Stemberger","year":"2014","unstructured":"Stemberger C, Graef P, Odendahl M, Albrecht J, Dossinger G, Anderl F, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood. 2014;124:628\u201337. https:\/\/doi.org\/10.1182\/blood-2013-12-547349.","journal-title":"Blood"},{"key":"1930_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.V128.22.1187.1187","volume":"128","author":"W Grubb","year":"2016","unstructured":"Grubb W, Samuel Huse S, Alam N, Dychter S, Wingard R, Maihail S, et al. Economic burden of acute graft-versus-host disease (GvHD) following allogeneic hematopoietic cell transplant (HCT). Blood. 2016;128:22.","journal-title":"Blood"},{"key":"1930_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10198-020-01249-x","volume":"22","author":"F Schain","year":"2021","unstructured":"Schain F, Batyrbekova N, Liwing J, Baculea S, Webb T, Remberger M, et al. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. Eur J Health Econ. 2021;22:169\u201380. https:\/\/doi.org\/10.1007\/s10198-020-01249-x.","journal-title":"Eur J Health Econ"},{"key":"1930_CR25","doi-asserted-by":"crossref","first-page":"1007.e1001","DOI":"10.1016\/j.jtct.2021.02.030","volume":"27","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Leather HL, Wang S, Burton N, IrizarryGatell V, Itzler R, et al. Severity of acute graft-versus-host disease and associated healthcare resource utilization, cost, and outcomes. Transplant Cell Ther. 2021;27:1007.e1001\u20138.","journal-title":"Transplant Cell Ther"},{"key":"1930_CR26","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1111\/ctr.12065","volume":"27","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, et al. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III\/IV acute GvHD. Clin Transplant. 2013;27:E56\u201363. https:\/\/doi.org\/10.1111\/ctr.12065.","journal-title":"Clin Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01930-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T09:03:52Z","timestamp":1683277432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01930-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-01930-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DM: Honoraria for consultancies: CSL Behring. MM: Honoraria for consultancies: CSL Behring. NQ and HJ: Consulting fees paid to Certara: CSL Behring. DR, MK, XZ and KT: employment: CSL Behring. AB: Consulting fees: CSL Behring, Neumentum, Healx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}